{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:41:52Z","timestamp":1793112112660,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10384-025-01229-9","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:03:58Z","timestamp":1752141838000},"page":"911-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-na\u00efve neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-0280","authenticated-orcid":false,"given":"Hidetaka","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Numaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Asatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10384-021-00869-x","volume":"65","author":"K Yamashiro","year":"2021","unstructured":"Yamashiro K, Oishi A, Hata M, Takahashi A, Tsujikawa A. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol. 2021;65:741\u201360.","journal-title":"Jpn J Ophthalmol"},{"key":"1229_CR2","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352.","journal-title":"Lancet"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/s00417-021-05293-y","volume":"259","author":"M Ohji","year":"2021","unstructured":"Ohji M, Okada AA, Sasaki K, Moon SC, Machewitz T, Takahashi K, et al. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study. Graefes Arch Clin Exp Ophthalmol. 2021;259:3637\u201347.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1038\/s41598-022-10578-1","volume":"12","author":"H Matsumoto","year":"2022","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2022;12:8195.","journal-title":"Sci Rep"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR\u202f: a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Numaga S, Mimura K, Asatori Y, Akiyama H. Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2024;68:531\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127:616\u201336.","journal-title":"Ophthalmology"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10384-022-00922-3","volume":"66","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Koizumi H, Tamashiro T, Itagaki K, Nakayama M, Maruko I, et al. Short-term results for brolucizumab in treatment-naive neovascular age-related macular degeneration: a Japanese multicenter study. Jpn J Ophthalmol. 2022;66:379\u201385.","journal-title":"Jpn J Ophthalmol"},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H. Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep. 2021;11:6759.","journal-title":"Sci Rep"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, et al. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep. 2023;13:8747.","journal-title":"Sci Rep"},{"key":"1229_CR11","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H. Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;261:2945\u201352.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ajo.2016.06.014","volume":"169","author":"JH Cho","year":"2016","unstructured":"Cho JH, Ryoo NK, Cho KH, Park SJ, Park KH, Woo SJ. Incidence rate of massive submacular hemorrhage and its risk factors in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2016;169:79\u201388.","journal-title":"Am J Ophthalmol"},{"key":"1229_CR13","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1891\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina"},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study. Retina. 2015;35:1569\u201376.","journal-title":"Retina"},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135:1206\u201313.","journal-title":"JAMA Ophthalmol."},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","volume":"122","author":"A Yamamoto","year":"2015","unstructured":"Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866\u201372.","journal-title":"Ophthalmology"},{"key":"1229_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00417-016-3467-y","volume":"255","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:311\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/biomedicines9091164","volume":"9","author":"Y Fukuda","year":"2021","unstructured":"Fukuda Y, Sakurada Y, Matsubara M, Hasebe Y, Sugiyama A, Kikushima W, et al. Comparison of outcomes between 3 monthly brolucizumab and aflibercept injections for polypoidal choroidal vasculopathy. Biomedicines. 2021;9:1164.","journal-title":"Biomedicines"},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000526044","volume":"245","author":"J Hoshino","year":"2022","unstructured":"Hoshino J, Matsumoto H, Mukai R, Nakamura K, Akiyama H. Intravitreal aflibercept versus brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 macular neovascularization: comparison of short-term outcomes. Ophthalmologica. 2022;245:413\u201320.","journal-title":"Ophthalmologica"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology. 2016;123:617\u201324.","journal-title":"Ophthalmology"},{"key":"1229_CR22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology. 2012;119:1621\u20137.","journal-title":"Ophthalmology"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:627\u201333.","journal-title":"Am J Ophthalmol"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00417-021-05517-1","volume":"260","author":"T Tamashiro","year":"2022","unstructured":"Tamashiro T, Tanaka K, Itagaki K, Nakayama M, Maruko I, Wakugawa S, et al. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol. 2022;260:1857\u201365.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1229_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2025.2476061","author":"MH Nowroozzadeh","year":"2025","unstructured":"Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: a pharmacovigilance analysis of the FAERS database. Ocul Immunol Inflamm. 2025. https:\/\/doi.org\/10.1080\/09273948.2025.2476061.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01229-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01229-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:13:06Z","timestamp":1762881186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01229-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01229-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Matsumoto, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju), Participation on a Data Safety Monitoring Board or Advisory Board (Novartis, Chugai); J. Hoshino, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju); S. Numaga, None; Y. Asatori, None; H. Akiyama, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events (Novartis, Chugai, Senju, Bayer, Santen, Otsuka, AMO, Pfizer, Wakamoto, Kowa, Eisa, HOYA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}